{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:32:51Z","timestamp":1791977571789,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.tips.2011.08.002","type":"journal-article","created":{"date-parts":[[2011,9,23]],"date-time":"2011-09-23T11:35:59Z","timestamp":1316777759000},"page":"700-707","source":"Crossref","is-referenced-by-count":96,"title":["Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials"],"prefix":"10.1016","volume":"32","author":[{"given":"Martina","family":"Lukasova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorin","family":"Tunaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Offermanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2011.08.002_bib0005","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.1938.02790090004002","article-title":"The use of nicotinic acid in the treatment of pellagra","volume":"110","author":"Spies","year":"1938","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2011.08.002_bib0010","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch. Biochem."},{"key":"10.1016\/j.tips.2011.08.002_bib0015","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.0954-6820.1963.tb17457.x","article-title":"Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro","volume":"173","author":"Carlson","year":"1963","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.tips.2011.08.002_bib0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.tips.2011.08.002_bib0025","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tips.2011.08.002_bib0030","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.231.4.360","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"Anonymous","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2011.08.002_bib0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.pharmtox.48.113006.094746","article-title":"Nicotinic acid: pharmacological effects and mechanisms of action","volume":"48","author":"Gille","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.tips.2011.08.002_bib0040","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1742-1241.2009.02099.x","article-title":"The mechanism and mitigation of niacin-induced flushing","volume":"63","author":"Kamanna","year":"2009","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.tips.2011.08.002_bib0045","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2011.08.002_bib0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1124\/pr.110.003301","article-title":"International Union of Basic and Clinical Pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B)","volume":"63","author":"Offermanns","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tips.2011.08.002_bib0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11883-009-0007-9","article-title":"Niacin: an old drug rejuvenated","volume":"11","author":"Kamanna","year":"2009","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.tips.2011.08.002_bib0060","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/ATVBAHA.109.201129","article-title":"Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids","volume":"30","author":"Wu","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.tips.2011.08.002_bib0065","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI41651","article-title":"Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells","volume":"121","author":"Lukasova","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2011.08.002_bib0070","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbrc.2008.08.041","article-title":"The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist","volume":"375","author":"Tang","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2011.08.002_bib0075","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2011.08.002_bib0080","doi-asserted-by":"crossref","first-page":"E540","DOI":"10.1152\/ajpendo.2001.280.3.E540","article-title":"Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production","volume":"280","author":"Wang","year":"2001","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2011.08.002_bib0085","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/ATVBAHA.108.164541","article-title":"Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins","volume":"28","author":"Lamon-Fava","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.tips.2011.08.002_bib0090","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cmet.2010.09.001","article-title":"Regulation of hepatic ApoC3 expression by PGC-1\u03b2 mediates hypolipidemic effect of nicotinic acid","volume":"12","author":"Hernandez","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2011.08.002_bib0095","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1172\/JCI109385","article-title":"Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism","volume":"63","author":"Shepherd","year":"1979","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2011.08.002_bib0100","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1172\/JCI108833","article-title":"High density lipoprotein metabolism in man","volume":"60","author":"Blum","year":"1977","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2011.08.002_bib0105","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/ncpcardio1251","article-title":"Microsomal triglyceride transfer protein inhibition-friend or foe?","volume":"5","author":"Joy","year":"2008","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"10.1016\/j.tips.2011.08.002_bib0110","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.bbrc.2007.02.079","article-title":"Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice","volume":"355","author":"Hernandez","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2011.08.002_bib0115","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/ATVBAHA.108.171363","article-title":"Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice","volume":"28","author":"van der Hoorn","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.tips.2011.08.002_bib0120","first-page":"II_16","article-title":"Abstract 190: A niacin receptor partial agonist, MK-0354, robustly reduces plasma free fatty acids and produces little flushing but fails to alter LDL-C, HDL-C, and triglycerides in humans","volume":"116","author":"Lai","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.tips.2011.08.002_bib0125","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrcardio.2010.200","article-title":"Novel HDL-directed pharmacotherapeutic strategies","volume":"8","author":"Degoma","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.tips.2011.08.002_bib0130","doi-asserted-by":"crossref","first-page":"b92","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis","volume":"338","author":"Briel","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.tips.2011.08.002_bib0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/07853890802609534","article-title":"Is high HDL cholesterol always good?","volume":"41","author":"Olsson","year":"2009","journal-title":"Ann. Med."},{"key":"10.1016\/j.tips.2011.08.002_bib0140","first-page":"950","article-title":"HDL: still a target for new therapies?","volume":"9","author":"Nicholls","year":"2008","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.tips.2011.08.002_bib0145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2011.08.002_bib0150","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/ATVBAHA.110.207142","article-title":"Cholesterol efflux potential and anti-inflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.tips.2011.08.002_bib0155","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.108.836346","article-title":"Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy","volume":"121","author":"Sorrentino","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.tips.2011.08.002_bib0160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/FJC.0b013e31820dc1db","article-title":"Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities","volume":"57","author":"Holzhauser","year":"2011","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.tips.2011.08.002_bib0165","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.atherosclerosis.2008.04.044","article-title":"Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells","volume":"202","author":"Ganji","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tips.2011.08.002_bib0170","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1742-7843.2008.00364.x","article-title":"Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional findings in endothelial cells","volume":"104","author":"Tavintharan","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.tips.2011.08.002_bib0175","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bcp.2005.11.019","article-title":"Niacin induces PPAR\u03b3 expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways","volume":"71","author":"Knowles","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2011.08.002_bib0180","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bcp.2003.09.014","article-title":"Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin","volume":"67","author":"Rubic","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2011.08.002_bib0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/ATVBAHA.108.179283","article-title":"Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.tips.2011.08.002_bib0190","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5551\/jat.3939","article-title":"Adipose tissue, inflammation and atherosclerosis","volume":"17","author":"Gustafson","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.tips.2011.08.002_bib0195","doi-asserted-by":"crossref","first-page":"E549","DOI":"10.1152\/ajpendo.91004.2008","article-title":"Niacin stimulates adiponectin secretion through the GPR109A receptor","volume":"296","author":"Plaisance","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2011.08.002_bib0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.atherosclerosis.2007.09.036","article-title":"Preferential increase in high-molecular weight adiponectin after niacin","volume":"198","author":"Westphal","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tips.2011.08.002_bib0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.atherosclerosis.2009.08.045","article-title":"Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin","volume":"209","author":"Digby","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tips.2011.08.002_bib0210","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","article-title":"Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans","volume":"98","author":"Morrow","year":"1992","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.tips.2011.08.002_bib0215","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid-induced flushing","volume":"115","author":"Benyo","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2011.08.002_bib0220","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells","volume":"70","author":"Beny\u00f3","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2011.08.002_bib0225","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/sj.jid.5700586","article-title":"Langerhans cells release prostaglandin D2 in response to nicotinic acid","volume":"126","author":"Maciejewski-Lenoir","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.tips.2011.08.002_bib0230","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1172\/JCI42273","article-title":"Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice","volume":"120","author":"Hanson","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2011.08.002_bib0235","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2011.08.002_bib0240","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1038\/sj.bjp.0707528","article-title":"Nicotinic acid: an old drug with a promising future","volume":"153","author":"Bodor","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2011.08.002_bib0245","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4065\/83.4.470","article-title":"Effects of niacin on glucose control in patients with dyslipidemia","volume":"83","author":"Goldberg","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.tips.2011.08.002_bib0250","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0002-9343(92)90689-9","article-title":"Hepatotoxicity associated with sustained-release niacin","volume":"93","author":"Dalton","year":"1992","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tips.2011.08.002_bib0255","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2011.08.002_bib0260","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2011.08.002_bib0265","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.tips.2011.08.002_bib0270","unstructured":"National Institutes of Health, (2011) NIH stops clinical trial on combination cholesterol treatment. NIH News May 16, 2011 (http:\/\/public.nhlbi.nih.gov\/newsroom\/home\/GetPressRelease.aspx?id=2792)"},{"key":"10.1016\/j.tips.2011.08.002_bib0275","unstructured":"Armitage, J. et al. (2007) Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE July 19, 2010 (http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00461630?term=hps2-thrive&rank=1)"},{"key":"10.1016\/j.tips.2011.08.002_bib0280","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/j.amjcard.2008.02.028","article-title":"Niacin use and cutaneous flushing: mechanisms and strategies for prevention","volume":"101","author":"Davidson","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.tips.2011.08.002_bib0285","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1368-5031.2006.00957.x","article-title":"Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment","volume":"60","author":"Oberwittler","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.tips.2011.08.002_bib0290","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.tips.2011.08.002_bib0295","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1172\/JCI36806","article-title":"\u03b2-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice","volume":"119","author":"Walters","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2011.08.002_bib0300","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1021\/jm800258p","article-title":"3-(1H-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice","volume":"51","author":"Semple","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2011.08.002_bib0305","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.nbd.2008.07.011","article-title":"Niaspan treatment improves neurological functional recovery in experimental autoimmune encephalomyelitis mice","volume":"32","author":"Zhang","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2011.08.002_bib0310","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2006.03094.x","article-title":"Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration","volume":"145","author":"Schilling","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tips.2011.08.002_bib0315","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","article-title":"Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study","volume":"372","author":"Kappos","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2011.08.002_bib0320","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1517\/13543784.2010.534778","article-title":"Dimethyl fumarate for multiple sclerosis","volume":"19","author":"Papadopoulou","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.tips.2011.08.002_bib0325","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nrd3465","article-title":"Trial watch: Phase III success for Biogen's oral multiple sclerosis therapy","volume":"10","author":"Anonymous","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2011.08.002_bib0330","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.nbd.2010.05.034","article-title":"Niaspan treatment induces neuroprotection after stroke","volume":"40","author":"Shehadah","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2011.08.002_bib0335","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/CCM.0b013e3181feeae4","article-title":"Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-\u03baB pathway","volume":"39","author":"Kwon","year":"2011","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.tips.2011.08.002_bib0340","doi-asserted-by":"crossref","first-page":"F106","DOI":"10.1152\/ajprenal.00126.2009","article-title":"Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure","volume":"297","author":"Cho","year":"2009","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.tips.2011.08.002_bib0345","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10517-006-0059-6","article-title":"Inflammatory degeneration of joint tissue in adjuvant arthritis after intraarticular treatment with the mixture of silver drug and nicotinic acid","volume":"140","author":"Mitrofanov","year":"2005","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.tips.2011.08.002_bib0350","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.clindermatol.2008.07.001","article-title":"Fumaric acid esters","volume":"26","author":"Rostami Yazdi","year":"2008","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.tips.2011.08.002_bib0355","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0006-291X(03)00342-5","article-title":"Molecular identification of nicotinic acid receptor","volume":"303","author":"Soga","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2011.08.002_bib0360","doi-asserted-by":"crossref","first-page":"9869","DOI":"10.1074\/jbc.M210695200","article-title":"Molecular identification of high and low affinity receptors for nicotinic acid","volume":"278","author":"Wise","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2011.08.002_bib0365","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1124\/mol.105.015750","article-title":"Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A\/PUMA-G)","volume":"68","author":"Tunaru","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2011.08.002_bib0370","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/sj.cdd.4402238","article-title":"Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A)","volume":"15","author":"Kostylina","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.tips.2011.08.002_bib0375","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1002\/1521-4141(200112)31:12<3714::AID-IMMU3714>3.0.CO;2-1","article-title":"PUMA-G, an IFN-\u03b3-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily","volume":"31","author":"Schaub","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tips.2011.08.002_bib0380","doi-asserted-by":"crossref","first-page":"27601","DOI":"10.1074\/jbc.M110.102947","article-title":"Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases","volume":"285","author":"Singh","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2011.08.002_bib0385","first-page":"362","article-title":"Expression and localization of GPR109A (PUMA-G\/HM74A) mRNA and protein in mammalian retinal pigment epithelium","volume":"15","author":"Martin","year":"2009","journal-title":"Mol. Vis."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614711001507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614711001507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T08:43:16Z","timestamp":1638780196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614711001507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":77,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0165614711001507"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2011.08.002","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}